Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selinexor + dexamethasone + ixazomib + pomalidomide
- Development stage
- Phase 2
- Lead developer
- Karyopharm Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
This is a four-drug combination regimen consisting of selinexor, dexamethasone, ixazomib, and pomalidomide. Selinexor is an oral selective inhibitor of nuclear export that targets exportin 1 (XPO1), leading to the nuclear retention and activation of tumor suppressor proteins and induction of apoptosis in malignant cells. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Ixazomib is an oral proteasome inhibitor that disrupts protein degradation pathways in cancer cells, leading to cell death. Pomalidomide is an immunomodulatory agent that enhances immune response against myeloma cells and inhibits angiogenesis. This combination has been investigated primarily for relapsed/refractory multiple myeloma[1][2][8].
- Brand names
- Xpovio (selinexor)Ninlaro (ixazomib)Pomalyst (pomalidomide)Decadron (dexamethasone)
- Other names
- SPdI regimen
02
Targets
CRBN (Cereblon)XPO1 (Exportin-1)GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on selinexor + dexamethasone + ixazomib + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selinexor + dexamethasone + ixazomib + pomalidomide.